ABSTRACT
SchistoFLRFamide (PDVDHVFLRFamide) is one of the endogenous FMRFamide-like neuropeptides found in the nervous system of the locust Schistocerca gregaria (Robb et al. 1989; Robb and Evans, 1990). FMRFamide-like neuropeptides modulate the actions of a wide variety of both skeletal and visceral muscles in insects (Evans and Myers, 1986a; Schoofs et al. 1993b) and have been suggested to act both as circulatory hormones and as locally released neurotransmitters (see discussion in Robb and Evans, 1990).
SchistoFLRFamide was originally isolated from the nervous system of Schistocerca gregaria using a combination of radioimmunoassay, HPLC and bioassay (Robb et al. 1989; Robb and Evans, 1990). Preliminary data indicate that it inhibits spontaneous contractions of the locust heart and has a complex dose-dependent effect upon contractions induced in the extensor tibiae muscle by stimulation of the slow excitatory motoneurone (Robb et al. 1989). In addition, SchistoFLRFamide has recently been shown to decrease the amplitude and frequency of myogenic contractions and to reduce basal tension in locust oviduct muscle (Peeff et al. 1993).
The present paper provides a more detailed account of the modulatory effect of SchistoFLRFamide on heart and skeletal muscle in the locust Schistocerca gregaria. The effects of the synthetic peptide were measured on the semi-isolated locust heart (Cuthbert and Evans, 1989). The results are expressed as the percentage change in the amplitude of the heartbeat and its frequency with respect to measurements obtained immediately before the application of the peptide. Measurements of heart rate and contraction amplitude were averaged over a 1 min period, starting (a) 1 min before the beginning of the peptide pulse, (b) 1 min after the start of the peptide pulse, (c) 4 min after the start of the peptide pulse and (d) 1 min after the end of the peptide pulse. The bioactivity of synthetic SchistoFLRFamide was also assayed on another well-defined FMRFamide bioassay preparation from the locust. The effects were measured on the twitch tension evoked in the extensor tibiae muscle of the hindleg of the locust by stimulating the slow excitatory motoneurone to this muscle at 1 Hz (Evans and Myers, 1986b). The results are expressed as the maximal effects on the twitch amplitude.
SchistoFLRFamide had a potent dose-dependent cardioinhibitory effect on both the amplitude and frequency of spontaneous contractions in the semi-isolated locust heart, with a threshold for an observable effect occurring between 10−9 and 10−8 mol l−1 (Fig. 1). At low concentrations (10−8 mol l−1) SchistoFLRFamide had a slight cardioinhibitory effect, which lasted only while the heart was exposed to the peptide, and the heart rate returned to pre-exposure levels within 2 min of peptide removal (Figs 1Aiii, 2A). At higher concentrations (10−8 to 10−5 mol l−1), SchistoFLRFamide had potent cardioinhibitory effects on both the amplitude and frequency of heart contraction (Figs 1, 2B). These effects were long-lasting and in many preparations were still visible more than 2 min after peptide removal from the superfusate (Fig. 1Aiii, Biii). Fig. 2B shows a preparation in which a 5 min pulse of 10−7 mol l−1 SchistoFLRFamide initially reduced both the frequency and amplitude of spontaneous contractions. The effect on the frequency of spontaneous contractions lasted for about 2 min after the removal of the peptide from the superfusate but, in this preparation, the contraction amplitude returned to control levels before the end of the pulse and was even potentiated by 35 s after the end of the pulse. In general, the effects of the peptide were observed for longer in the wash-out period when higher concentrations were applied (see Robb et al. 1989). At 10−6 mol l−1 SchistoFLRFamide these effects were more pronounced (see Robb et al. 1989). Heart contractions were rapidly abolished, an effect that persisted for several minutes after the peptide had been removed from the superfusate. As heartbeat frequency began to recover during the wash-out, contraction amplitude was always potentiated for several minutes. These potentiating effects of high doses of SchistoFLRFamide are not visible in the dose–response curves (Fig. 1); they did not occur until several minutes after the peptide had been removed from the superfusate.
SchistoFLRFamide also produced a complex dose-dependent pattern of potentiation and inhibition on both the amplitude and relaxation rate of slow-motoneurone-induced twitch tension in the extensor tibiae muscle of the locust hindleg. At concentrations between 10−12 and 10−8 mol l−1, SchistoFLRFamide produced a small but variable increase of 10–20% in the amplitude of twitch tension. At higher concentrations, between 10−7 and 10−5 mol l−1, the amplitude responses were complex and varied between preparations. In most preparations (six out of seven) the responses were excitatory (e.g. Fig. 3i), but in one preparation the amplitude of twitch tension was reduced at all concentrations tested. Many of the excitatory responses were biphasic, with an initial transient inhibition preceding the main excitatory response. Fig. 3ii shows a preparation in which a biphasic response was induced at 10−6 mol l−1 but in which exposure to 10−5 mol l−1 peptide produced purely a large excitation, whilst Fig. 3iii shows a preparation in which excitation was produced at 10−8 mol l−1, inhibition at 10−7 mol l−1 and 10−6 mol l−1 and a biphasic effect at 10−5 mol l−1. Possible reasons for the different degrees of inhibition and excitation shown by individual preparations are currently being investigated. Similar biphasic results were obtained for the effect of SchistoFLRFamide on the relaxation rate of slow-motoneurone-induced twitch tension (data not shown).
ACKNOWLEDGEMENTS
Previous physiological investigations have provided evidence for the existence of at least two receptors for FMRFamide-like peptides in locusts, one producing excitation and the other inhibition in a number of preparations, including the extensor tibiae muscle of the hindleg (Evans and Myers, 1986a,b; Cuthbert and Evans, 1989), the heart (Cuthbert and Evans, 1989) and the oviducts (Peeff et al. 1993). Concentration-dependent biphasic effects of FMRFamide have also been reported in studies on hearts from a number of bivalve molluscs (Painter and Greenberg, 1982). Evidence has also been presented for the existence of multiple receptor types for members of this peptide family on molluscan neurones (Cottrell et al. 1984; Ruben et al. 1986; Cottrell and Davies, 1987), skeletal muscle (Cottrell et al. 1983) and heart (Payza, 1987). In the present paper, the most likely explanation for our results with SchistoFLRFamide is that this neuropeptide is capable of activating both excitatory and inhibitory subtypes of receptors in both the locust heart and extensor tibiae muscle preparations. However, in the absence of specific antagonists for these receptors, it is not possible to rule out a mechanism whereby the native peptide is acting on only a single class of receptors, whose effects vary according to the level of receptor activation. This explanation seems to be unlikely, however, since the closely related neuropeptide leucomyosuppressin, in which a single N-terminal amino acid, pyroglutamate, is substituted for the proline of SchistoFLRFamide, interacts exclusively with the inhibitory subclass of FMRFamide-like receptors (Evans and Myers, 1986a,b; Cuthbert and Evans, 1989). The exact responses obtained by the application of SchistoFLRFamide in these systems depended both on the concentration of the peptide used and on the response characteristics of the individual preparation. Thus, a detailed characterization of the pharmacology and mode of action of SchistoFLRFamide in these tissues awaits either the development of specific antagonists for the receptor subtypes or their cloning.